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Background:  Plasma levels of alkaline phosphatase, alanine aminotransferase (ALT), 
aspartate aminotransferase, and γ-glutamyl transferase (GGT) are often elevated in 
cardiometabolic diseases.  We investigated if hypertension is associated with elevated levels 
of these plasma markers. 
Methods:  We included 235 hypertensive and 708 normotensive subjects (mean age 47.3±9.6 
and 58.0±10.2 years respectively) from the Hong Kong Cardiovascular Risk Factor 
Prevalence Study-2 (CRISPS-2) in 2000-2004 who had drank less than once per week.  In the 
follow-up study in 2005-2008 (CRISPS-3), 126 out of the 708 subjects had developed 
hypertension. 
Results:  Raised plasma ALT (OR=1.22 per SD of log-transformed level, P=0.045) and 
GGT (OR=1.38 per SD of log-transformed level, P=0.001) levels were associated with 
hypertension at baseline in CRISPS-2 after adjusting for covariates.  Among subjects not on 
anti-hypertensive medications, plasma ALP, ALT and GGT were related to blood pressure 
(P<0.01).  In subjects normotensive at CRISPS-2, plasma GGT, but not ALP, ALT and AST, 
was an independent predictor of new-onset hypertension at CRISPS-3 (OR=1.38 per SD of 
log-transformed level, P=0.020 and OR=2.68 for 3rd tertile vs. 1st tertile, P=0.004) after 
adjusting for covariates.   
Conclusions:  Among the four plasma markers, elevated GGT level is the strongest predictor 
for existing and new-onset hypertension in Hong Kong Chinese.  
 





Non-alcoholic fatty liver disease (NAFLD) is caused by the accumulation of fat in the 
liver in subjects who do not drink alcohol in excess [1].  It has recently been suggested as the 
hepatic manifestation of obesity and the metabolic syndrome [1].  In NAFLD, plasma 
markers of liver injury such as alkaline phosphatase (ALP), alanine aminotransferase (ALT), 
aspartate aminotransferase (AST), and γ-glutamyl transferase (GGT) are often elevated [2].   
 
Apart from liver diseases, these enzymes, especially GGT, have been suggested to be 
novel markers of cardiovascular diseases [3].  Elevated plasma GGT level has been shown to 
be associated with hypertension and its development in previous studies in Japanese [4-6], 
Korean [7], and Caucasians [8,9].  However, all these studies investigated GGT but not the 
other enzymes, i.e. ALP, ALT, and AST [4-9].  We previously reported that plasma ALP 
correlates with the inflammatory marker, C-reactive protein (CRP), in Hong Kong Chinese 
[10] and Americans [11].  As CRP is known to predict the development of hypertension [12], 
ALP may also be related to the latter.  Moreover, elevated plasma ALT is already known to 
precede the development of the metabolic syndrome [2] and type 2 diabetes [13-17].  
Therefore, we hypothesized that plasma markers of liver injury other than GGT may also be 
elevated in hypertension and predict the future risk of hypertension.  If this hypothesis is true, 
the routine liver function test may help to monitor the risk at minimal extra cost.  As there is 
no prospective study on the relationship of hypertension with all the four plasma markers of 
liver injury, especially in Chinese, we investigated whether plasma ALP, ALT, AST, and 
GGT were associated with hypertension in a population-based prospective cohort of Hong 
Kong Chinese.  Since alcohol drinking can increase plasma markers of liver injury and may 




have confounding effect, we limited our analysis to subjects who had alcoholic drinks less 




The subjects were from the Hong Kong Cardiovascular Risk Factor Prevalence Study-
2 (CRISPS-2), details of which have been described previously [18-21].  The study protocol 
was approved by the Ethics Committee of the University of Hong Kong and all subjects gave 
written and informed consent.  Among the 1944 subjects in the CRISPS-2 study in 2000-
2004, plasma levels of all the four markers of liver injury were available in 1371 subjects, 
and only 1197 of whom had alcoholic drinks less often than once a week.  Among these 
subjects, 943 were followed up in 2005-2008 (CRISPS-3) after a median interval of 5.3 years 
and were included in this analysis. 
 
2.2. Variables of interest 
Plasma ALP, ALT, AST, and GGT were measured on a Hitachi 912 analyzer.  
Hypertension was defined as systolic blood pressure (SBP) ≥140 mmHg, diastolic blood 
pressure (DBP) ≥90 mmHg, or taking anti-hypertensive medication.  Blood pressure was 
measured three times using a mercury sphygmomanometer by a trained nurse.  The readings 
were taken in a seated position after resting in a quiet temperature-controlled room.  The 
Korotkoff V sound was used to determine DBP.  The first measurement was to familiarize the 
subject with the procedure and the sensation of the inflated cuff.  The mean of the second and 
third readings was used for data analysis.  Mean arterial pressure (MAP) was calculated as 
the sum of DBP and one-third of the difference between SBP and DBP.  Data on alcohol 




drinking, smoking, and history of hypertension were obtained by interviewing using a 
questionnaire.  Details of the physical examination and measurement methods of clinical 
parameters, such as triglycerides, high-density lipoprotein (HDL) cholesterol, low-density 
lipoprotein (LDL) cholesterol, fasting glucose, homeostasis model assessment of insulin 
resistance index (HOMA-IR), fibrinogen, and plasma high-sensitivity CRP had been 
described previously [18-23]. 
 
2.3. Statistical analysis 
Statistical analysis was performed using SPSS 18.0 (SPSS Inc., Chicago, IL).  
Variables with skewed distribution were log-transformed before analysis.  Multiple linear or 
logistic regression models were used to estimate the standardized regression coefficient (β) or 
odds ratio (OR) respectively after adjusting for covariates.  Variables were used as covariates 
in the multiple regression analysis if they are recognized determinants of blood pressure or 
were significantly different between subjects with and without hypertension.  For variables 
that were highly correlated such as body mass index (BMI) and waist circumference, only 
one was entered into the regression analysis.  In a separate analysis, similar results were 
obtained when BMI was replaced by waist circumference in the adjustment model.  The P 
values for interaction were estimated by including each multiplicative interaction term in the 
multivariate regression models in full sample after adjusting for the main effects of all 
covariates.  A two-tailed P<0.05 was considered statistically significant.  
 
3. Results 
Table 1 shows the clinical characteristics of the subjects in CRISPS-2 according to the 
hypertension status.  Among 708 subjects normotensive in CRISPS-2, 126 subjects had 




developed hypertension in CRISPS-3.  As expected, subjects with prevalent or incident 
hypertension were older, had higher BMI, waist circumference, SBP, DBP, MAP, 
triglycerides, fasting blood glucose and HOMA-IR, and had lower HDL cholesterol.  
Subjects hypertensive at baseline had a higher plasma fibrinogen level but less likely to be 
smokers.   
 
In CRISPS-2, all the four plasma markers of liver injury were higher in subjects with 
prevalent hypertension (Table 1).  Among 809 subjects not on anti-hypertensive medication 
in CRISPS-2, the plasma levels of most markers were significantly associated with SBP 
(ALP: β=0.185, P<0.001; ALT: β=0.137, P=0.001; and GGT: β=0.155, P<0.001), DBP (ALP: 
β=0.184, P<0.001; ALT: β=0.149, P<0.001; AST: β=0.088, P=0.011; and GGT: β=0.171, 
P<0.001), and MAP (ALP: β=0.200, P<0.001; ALT: β=0.156, P<0.001; AST:  β=0.081, 
P=0.015; and GGT: β=0.178, P<0.001) after adjusting for age and sex.  In a separate analysis, 
inclusion of the 134 treated subjects using adjusted blood pressure (by adding 10/5 mmHg to 
blood pressure24) produced similar results (data not shown).  As women had significantly 
lower plasma levels of all the four markers than men (P<0.001 after adjusting for age and 
BMI), sex-specific cut-points were used to define the tertiles of the plasma levels in 
subsequent analysis.  As shown in Table 2, plasma GGT were significantly associated with 
prevalent hypertension in the full adjustment model (P=0.003 for continuous data and P for 
trend = 0.008 for tertiles).  Plasma ALT was also associated with prevalent hypertension with 
a borderline significant P value of 0.045 when the plasma level was analyzed as continuous 
data.  There was no significant interaction of plasma GGT and ALT with sex (P >0.05).  The 
clinical characteristics of subjects according to the sex-specific tertiles of plasma GGT levels 
are shown in Table 3.  In CRISPS-2, plasma GGT level increased with increasing age, BMI, 




waist circumference, SBP, DBP, MAP, triglycerides, LDL cholesterol, fasting glucose,  
HOMA-IR, plasma CRP, plasma ALP, plasma ALT and plasma AST, and decreased with 
increasing HDL cholesterol (all P<0.05, Table 3).  Plasma fibrinogen and the proportion of 
smoking did not differ significantly with plasma GGT tertiles.   
 
Among subjects normotensive in CRISPS-2, those who had developed hypertension 
in CRISPS-3 had significantly higher plasma levels of ALP, ALT, and GGT (Table 1).  
However, only the association of plasma GGT with incident hypertension remained 
significant in the full adjustment model (Table 4).  There was no significant interaction of 
plasma GGT with sex (P=0.207 for tertiles and 0.072 for continuous level) and other 
covariates (P>0.05 after adjustment for multiple testing).  The association of plasma GGT 
tertiles with incident hypertension was significant in subjects with BMI <25.0 kg/m2 and 
BMI ≥25.0 kg/m2 (P for trend =0.038 and 0.042 respectively). Similar results were obtained 




This is the first report of the relationship between all the four plasma markers of liver 
injury and hypertension in a population-based prospective cohort.  We demonstrated that only 
plasma GGT, but not the other markers, was associated with hypertension at baseline and 
incident hypertension.   
 
Our results are consistent with previous findings on the association of plasma GGT 
with hypertension or pre-hypertension in cross-sectional [25-28] and prospective studies [4-9].  




The mechanisms underlying the association of GGT with hypertension have not been fully 
elucidated.  Plasma GGT is usually used as a marker of alcohol intake.  In this study, the 
subjects were not regular alcohol drinkers, but elevated GGT level was still associated with 
both prevalent and incident hypertension.  Previous studies also found a similar association in 
both drinkers and non-drinkers [8,26].  Therefore, the association cannot be explained by 
alcohol drinking.   
 
Recently, GGT has been suggested as a novel biomarker of cardiovascular risk [3].  
Its elevated level has been shown to be associated with the metabolic syndrome in cross-
sectional studies [29,30].  In prospective studies, elevated GGT level can predict incident 
elevation in plasma ALT [31], and the development of cardiovascular diseases, all-cause 
mortality, and cardiovascular mortality [30,32-34].  In the Framingham Offspring Study, 
plasma GGT correlated positively with BMI, blood pressure, LDL cholesterol, triglycerides 
and fasting glucose in cross-sectional analysis, and predicted the development of the 
metabolic syndrome and cardiovascular diseases over a period of 20 years [35].  It has been 
suggested that the association of plasma GGT with the metabolic syndrome may be explained 
by insulin resistance [36].  Indeed, plasma GGT has also been reported to be predictive of 
incident diabetes [8,37,38] and the close relationship between raised blood pressure and 
dysglycemia in our population may also contribute to the association of plasma GGT with 
hypertension [21].  However, in our study, plasma GGT predicted incident hypertension, 
even after adjusting for covariates including the insulin resistance index, HOMA-IR.  Plasma 
GGT has been suggested as a marker of oxidative stress [3,39], a risk factor of hypertension 
and cardiovascular diseases.  GGT is a key enzyme in the catabolism of glutathione and plays 
a role in the production of reactive oxygen species through modulating the redox status of 




cell surface protein thiols [40].  In a clinical study, serum levels of antioxidants can predict 
GGT level at 10 year, but not vice versa [39].  A prospective study of American adults 
revealed significant association of plasma GGT with hypertension only among subjects who 
were overweight or had increased central body fat [9].  This may suggest fatty liver as an 
underlying mechanism for the association of plasma GGT with hypertension.  Our previous 
work suggested that plasma GGT correlates with plasma CRP [10,11], so elevated GGT may 
reflect inflammation that occurs in fatty liver.  
 
Plasma ALP was associated with blood pressure among subjects not on anti-
hypertensive medication in CRISPS-2.  Although plasma ALP tertiles were not significantly 
related to hypertension, plasma ALP correlated with SBP and DBP when these were treated 
as continuous variables.   The association of plasma ALP with blood pressure could be 
explained at least in part by its correlation with plasma GGT levels [10,11,41].  Elevated 
plasma ALT is associated with the development of the metabolic syndrome [2] and type 2 
diabetes [13-17], which are closely related to hypertension in our population [19,21].  In our 
study, plasma ALT was not an independent predictor of prevalent and incident hypertension 
in stepwise logistic regression analysis.   
 
There are some limitations in this study.  The cohort of this study is community-based 
and so the number of subjects with prevalent and incident hypertension is relatively small.  
The degree of variations in plasma ALP, ALT, AST, and GGT among subjects and within an 
individual may influence the degree of significance of their association with hypertension.  
Elevation of ALP, ALT, AST, and GGT in plasma can be non-specific and found in other 
diseases such as hepatitis, biliary diseases, musculoskeletal diseases, and myocardial injury.  




However, these non-specific causes of elevation in plasma markers of liver injury are likely 
to diminish rather than augment the observed association.   
 
In conclusion, among the four plasma markers of liver injury, GGT is the strongest 
risk factor for hypertension in Hong Kong Chinese.  Therefore, further studies to assess the 
utility of GGT as a biomarker for hypertension and related diseases are warranted. 
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Table 1   
Clinical characteristics of the subjects in CRISPS-2 (2000-2004). 












Age (years) 47.3±9.7 58.0±10.2‡ 46.0±9.0 53.3±10.3‡ 
Women (%) 60.5 51.1 61.0 57.9 
BMI (kg/m2) 23.3±3.3 25.4±3.4‡ 23.1±3.0 24.5±4.0‡ 
Waist circumference 
(cm) 
77.3±9.5 84.1±9.4‡ 76.7±9.2 80.5±10.4‡ 
SBP (mmHg)§ 113.3±10.9 147.9±15.5‡ 111.2±10.0 123.1±9.5‡ 
DBP (mmHg)§ 72.0±8.1 89.0±11.5‡ 71.0±8.0 76.6±7.1‡ 
MAP (mmHg)§ 85.8±8.2 108.7±9.5‡ 84.4±7.8 92.1±6.8‡ 
Triglycerides 
(mmol/l) 
1.07 (1.03-1.11) 1.45 (1.35-1.55)‡ 1.03 (0.99-1.07) 1.26 (1.15-1.38)† 
HDL cholesterol 
(mmol/l) 
1.45±0.39 1.33±0.38‡ 1.46±0.38 1.39±0.41† 
LDL cholesterol 
(mmol/l) 
3.21±0.81 3.36±0.78 3.20±0.80 3.25±0.85 
Fasting glucose 
(mmol/l)  
5.13 (5.06-5.19) 5.55 (5.41-5.69)* 5.05(4.99-5.11) 5.52 (5.31-5.75)‡ 
HOMA-IR  1.57 (1.51-1.64) 2.29 (2.10-2.49)‡ 1.50 (1.43-1.57) 1.95 (1.77-2.14)‡ 
Fibrinogen (g/l) 2.90±0.54 3.11±0.62* 2.89±0.56 2.97±0.47 
CRP (mg/l) 0.51 (0.47-0.55) 0.85 (0.75-0.96)‡ 0.47 (0.43-0.51) 0.74 (0.64-0.86)‡ 
ALP (U/l) 66.1 (64.7-67.6) 77.2 (74.5-80.0)† 64.8 (63.2-66.3) 72.7 (68.9-76.6)† 
ALT (U/l) 20.0 (19.2-20.9) 24.6 (22.9-26.4)‡ 19.5 (18.7-20.4) 22.5 (20.1-25.0)† 
AST (U/l) 21.6 (21.0-22.2) 24.2 (23.2-25.4)* 21.5 (20.9-22.1) 23.0 (21.5-24.7) 
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GGT (U/l) 20.5 (19.7-21.4) 28.2 (26.1-30.6)‡ 19.8 (18.9-20.8) 24.1 (21.6-26.9)‡ 
Current smoking (%) 15.1 10.6* 15.3 14.3 
Data are expressed as mean±SD or geometric mean (95% CI) unless otherwise stated.  
*P<0.05, †P<0.01, and ‡P<0.001 for normotensive versus hypertensive subjects after 
adjusting for age and sex.  For incident elevated blood pressure, P values were further 
adjusted for follow-up duration.   
§Subjects on anti-hypertensive medication (n=134) were excluded from analysis. 
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Table 2   
Association with prevalent hypertension in CRISPS-2 (n=943). 
Liver enzyme Unadjusted model Model 1 Model 2 
 OR (95% CI) P OR (95% CI) P OR (95% CI) P 
ALP tertile       
Tertile 1  1.00 (referent)  1.00 (referent)  1.00 (referent)  
Tertile 2  1.46 (0.99-2.16) 0.057 1.33 (0.86-2.04) 0.204 1.13 (0.71-1.82) 0.603 
Tertile 3  2.60 (1.79-3.77) <0.001 1.66 (1.10-2.52) 0.017 1.15 (0.72-1.84) 0.552 
P for trend  <0.001  0.058  0.821 
ALP, U/l* 1.76 (1.49-2.08) <0.001 1.37 (1.15-1.64) 0.001 1.23 (0.99-1.52) 0.061 
       
ALT tertile       
Tertile 1 1.00 (referent)  1.00 (referent)  1.00 (referent)  
Tertile 2 1.73 (1.18-2.54) 0.005 1.64 (1.06-2.53) 0.025 1.13 (0.71-1.81) 0.605 
Tertile 3 2.56 (1.75-3.73) <0.001 3.11 (2.02-4.77) <0.001 1.59 (0.98-2.57) 0.060 
P for trend  <0.001  <0.001  0.130 
ALT, U/l* 1.42 (1.22-1.64) <0.001 1.56 (1.31-1.87) <0.001 1.22 (1.01-1.49) 0.045 
       
AST tertile       
Tertile 1  1.00 (referent)  1.00 (referent)  1.00 (referent)  
Tertile 2  1.44 (0.99-2.09) 0.058 1.20 (0.79-1.82) 0.394 1.05 (0.67-1.64) 0.842 
Tertile 3  2.09 (1.45-3.00) <0.001 1.74 (1.16-2.61) 0.007 1.43 (0.93-2.21) 0.107 
P for trend  <0.001  0.022  0.210 
AST, U/l* 1.36 (1.17-1.57) <0.001 1.25 (1.06-1.47) 0.008 1.16 (0.97-1.38) 0.103 
       
GGT tertile       
Tertile 1 1.00 (referent)  1.00 (referent)  1.00 (referent)  
Tertile 2  1.62 (1.08-2.43) 0.020 1.43 (0.91-2.24) 0.120 1.12 (0.69-1.81) 0.656 
Tertile 3 3.71 (2.54-5.41) <0.001 3.77 (2.46-5.77) <0.001 1.99 (1.21-3.26) 0.007 
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P for trend  <0.001  <0.001  0.008 
GGT, U/l* 1.65 (1.42-1.91) <0.001 1.73 (1.45-2.06) <0.001 1.38 (1.12-1.70) 0.003 
For ALP, the cut-off values for tertiles 1, 2, and 3 are ≤67, 68-82 and ≥83 U/l in men, and 
≤57, 58-74 and ≥75 U/l in women, respectively. 
For ALT, the cut-off values for tertiles 1, 2, and 3 are ≤20, 21-31 and ≥32 U/l in men, and 
≤14, 15-21 and ≥22 U/l in women, respectively. 
For AST, the cut-off values for tertiles 1, 2, and 3 are ≤21, 22-26 and ≥27 U/l in men, and 
≤18, 19-23 and ≥24 U/l in women, respectively. 
For GGT, the cut-off values for tertiles 1, 2, and 3 are ≤21, 22-33 and ≥34 U/l in men, and 
≤14, 15-21 and ≥22 U/l in women, respectively. 
Model 1: Adjusted for age and sex.   
Model 2: Further adjusted for BMI, triglycerides, HDL cholesterol, HOMA-IR, CRP, 
fibrinogen, and current smoking. 
*ORs are expressed in term of per SD of the log-transformed unit.
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Table 3   
Clinical characteristics of the subjects in CRISPS-2 according to tertiles of plasma GGT level. 
Characteristics Tertile 1 
(≤21 U/L in men 
and ≤14 U/L in 
women) 
Tertile 2 
(22-33 U/L in men 
and 15-21 U/L in 
women) 
Tertile 3 
(≥34 U/L in men 




n 338 301 304  
Age (years) 48.3±10.6 50.6±10.6 51.1±11.1 0.004 
BMI  (kg/m2) 22.8±2.9 23.7±3.2 25.2±3.8 <0.001 
Waist circumference (cm) 75.7±8.8 79.3±9.4 82.5±10.3 0.003 
SBP (mmHg)* 114.9±14.4 117.2±15.2 121.8±18.8 0.013 
DBP (mmHg)* 72.6±9.4 73.9±9.3 76.6±11.8 0.039 
MAP (mmHg)* 86.7±10.2 88.3±10.4 91.7±12.9 0.014 
Triglycerides (mmol/l) 0.93 (0.89-0.97) 1.13 (1.07-1.19) 1.50 (1.42-1.60) <0.001 
HDL cholesterol (mmol/l) 1.43±0.35 1.37±0.37 1.28±0.39 0.009 
LDL cholesterol (mmol/l) 3.17±0.80 3.21±0.74 3.37±0.86 0.026 
Fasting glucose (mmol/l) 5.03 (4.96-5.10) 5.22 (5.12-5.31) 5.47 (5.34-5.61) <0.001 
HOMA-IR  1.34 (1.27-1.41) 1.71 (1.60-1.83) 2.31 (2.16-2.48) <0.001 
Fibrinogen (g/l) 2.90±0.57 2.92±0.51 3.04±0.62 0.158 
CRP (mg/l) 0.40 (0.36-0.45) 0.60 (0.54-0.67) 0.82 (0.74-0.91) <0.001 
ALP (U/l) 61.4 (59.6-63.2) 69.2 (67.2-71.3) 77.3 (74.7-80.0) <0.001 
ALT (U/l) 15.9 (15.1-16.6) 19.9 (19.0-20.9) 30.5 (28.5-32.7) <0.001 
AST (U/l) 19.6 (19.0-20.2) 21.5 (20.9-22.2) 26.3 (25.0-27.6) <0.001 
Current smoking (%) 12.4 15.3 14.5 0.351 
Hypertension (%) 14.8 21.9 39.1 <0.001 
Data are expressed as mean±SD or geometric mean (95% CI) unless otherwise stated.  
P for trend was adjusted for age, sex, and BMI, where appropriate. 
*Subjects on anti-hypertensive medication were excluded from analysis. 
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Table 4   
Association with incident hypertension in CRISPS-3 (n=708). 
Liver enzyme Unadjusted model Model 1 Model 2 
 OR (95% CI) P OR (95% CI) P OR (95% CI) P 
ALP tertile       
Tertile 1  1.00 (referent)  1.00 (referent)  1.00 (referent)  
Tertile 2  1.89 (1.11-3.22) 0.019 1.60 (0.88-2.90) 0.124 1.48 (0.79-2.77) 0.218 
Tertile 3 2.98 (1.79-4.95) <0.001 1.66 (0.94-2.94) 0.083 1.48 (0.80-2.74) 0.212 
P for trend  <0.001  0.185  0.385 
ALP, U/l* 1.49 (1.21-1.83) <0.001 1.14 (0.90-1.43) 0.283 1.08 (0.82-1.42) 0.593 
       
ALT tertile       
Tertile 1  1.00 (referent)  1.00 (referent)  1.00 (referent)  
Tertile 2  1.44 (0.87-2.36) 0.153 1.36 (0.78-2.40) 0.279 1.19 (0.65-2.18) 0.566 
Tertile 3 1.82 (1.11-2.98) 0.017 1.59 (0.91-2.77) 0.104 1.30 (0.69-2.43) 0.416 
P for trend  0.057  0.260  0.714 
ALT, U/l* 1.26 (1.05-1.51) 0.012 1.32 (1.05-1.67) 0.018 1.20 (0.92-1.56) 0.181 
       
AST tertile       
Tertile 1  1.00 (referent)  1.00 (referent)  1.00 (referent)  
Tertile 2  1.11 (0.68-1.81) 0.674 1.01 (0.58-1.77) 0.968 1.12 (0.63-2.02) 0.697 
Tertile 3 1.66 (1.03-2.66) 0.037 1.44 (0.82-2.50) 0.202 1.47 (0.82-2.64) 0.198 
P for trend  0.080  0.332  0.408 
AST, U/l* 1.22 (1.03-1.46) 0.026 1.20 (0.96-1.49) 0.105 1.15 (0.91-1.45) 0.256 
       
GGT tertile       
Tertile 1 1.00 (referent)  1.00 (referent)  1.00 (referent)  
Tertile 2 1.54 (0.90-2.63) 0.115 1.28 (0.69-2.35) 0.434 1.16 (0.60-2.22) 0.661 
Tertile 3  2.81 (1.69-4.66) <0.001 2.93 (1.63-5.24) <0.001 2.68 (1.36-5.26) 0.004 
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P for trend  <0.001  <0.001  0.004 
GGT, U/l* 1.36 (1.13-1.62) 0.001 1.43 (1.14-1.79) 0.002 1.38 (1.05-1.81) 0.020 
For ALP, the cut-off values for tertiles 1, 2, and 3 are ≤67, 68-81 and ≥82 U/l in men, and 
≤54, 55-70 and ≥71 U/l in women, respectively. 
For ALT, the cut-off values for tertiles 1, 2, and 3 are ≤19, 20-31 and ≥32 U/l in men, and 
≤13, 14-19 and ≥20 U/l in women, respectively. 
For AST, the cut-off values for tertiles 1, 2, and 3 are ≤20, 21-25 and ≥26 U/l in men, and 
≤17, 18-22 and ≥23 U/l in women, respectively. 
For GGT, the cut-off values for tertiles 1, 2, and 3 are ≤19, 20-30 and ≥31 U/l in men, and 
≤13, 14-19 and ≥20 U/l in women, respectively. 
Model 1: Adjusted for age, sex, and systolic blood pressure at baseline and follow-up 
duration. 
Model 2: Further adjusted for baseline BMI, triglycerides, HDL cholesterol, HOMA-IR, CRP, 
fibrinogen, current smoking, and change in BMI. 
*ORs are expressed in term of per SD of the log-transformed unit. 
 
 
